Stay updated on BIONIKK Trial: Nivolumab vs VEGFR tKi in Kidney Cancer

Sign up to get notified when there's something new on the BIONIKK Trial: Nivolumab vs VEGFR tKi in Kidney Cancer page.
Latest website image capture
Clouds background image

Latest updates to the BIONIKK Trial: Nivolumab vs VEGFR tKi in Kidney Cancer page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the study plan for a Phase 2 BIOmarker Driven Trial involving Nivolumab, Ipilimumab, and VEGFR tKi in Naïve Metastatic Kidney Cancer, focusing on molecular group determination and treatment strategies for metastatic renal cell carcinoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:40:08.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying requirements such as histological confirmation of RCC with a clear-cell component and TFE3 or TFEB translocation. Previously, this section only indicated that no information was provided.
    Difference
    36%
    Check dated 2024-05-22T21:36:51.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:37:22.000Z thumbnail image

Stay in the know with updates to BIONIKK Trial: Nivolumab vs VEGFR tKi in Kidney Cancer

Enter your email address, and we'll notify you when there's something new on the BIONIKK Trial: Nivolumab vs VEGFR tKi in Kidney Cancer page.